

Hepatitis C Virus Infection (HCV) Bibliography: September 2019

Essential Overview/Background

1. Thomas DL. Global Elimination of Chronic Hepatitis. *N Engl J Med*. 2019 May 23;380(21):2041-2050. PMID: 31116920
<https://www.ncbi.nlm.nih.gov/pubmed/31116920/>
2. Marks K, Naggie S. Management of Hepatitis C in 2019. *JAMA*. 2019 May 17; PMID: 31099822.
<https://jamanetwork.com/journals/jama/fullarticle/2734262>
3. Hepatitis C Guidance 2018 Update: AASLD-IDS A Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis*. 2018 Oct 30;67(10):1477-1492. PMID: 30215672
<https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciy585>
4. Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. *Clin Ther*. 2018 Aug;40(8):1234-1245. PMID: 29983266
<https://jumpshare.com/v/F4SHY4XQZ4IZQSJeAnhA>
5. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. 2018 Jul. PMID: 30307724
<https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/>
6. Lok AS, Chung RT, Vargas HE, et al. Benefits of Direct-Acting Antivirals for Hepatitis C. *Ann Int Med*. 2017 Dec 5;167(11):812-813. PMID: 29049502
<https://annals.org/aim/article-abstract/2657699/benefits-direct-acting-antivirals-hepatitis-c>
7. Hepatitis C: State of Medicaid Access. National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation at Harvard Law School. Oct 2017.
<https://stateofhepc.org/>
8. Wolitski, R. Report from an Expert Consultation on the Evidence for Early Treatment of HCV in the United States. U.S. Department of Health & Human Services. Feb 2017.
9. Naggie S, Holland DP, Sulkowski MS, Thomas DL. Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. *Clin Infect Dis*. 2017 Jan 1;64(1):92-99. PMID: 27682067
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159603/pdf/ciw656.pdf>
10. National Viral Hepatitis Action Plan 2017-2020. U.S. Department of Health and Human Services. Jan 2017.
<https://www.hhs.gov/sites/default/files/National%20Viral%20Hepatitis%20Action%20Plan%202017-2020.pdf>
11. Barocas JA, Linas BP. Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis. *Clin Infect Dis*. 2017 Jan 1;64(1):100-101. PMID: 27815292
<https://academic.oup.com/cid/article/64/1/100/2496613>
12. Wakeman SE. Medications For Addiction Treatment: Changing Language to Improve Care. *J Addict Med*. 2017 Jan/Feb;11(1):1-2. PMID: 27898497
<https://insights.ovid.com/pubmed?pmid=27898497>

13. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. National Academies of Sciences, Engineering, and Medicine. Washington, DC: *The National Academies Press*. 2017.
https://www.ncbi.nlm.nih.gov/books/NBK442227/pdf/Bookshelf_NBK442227.pdf
14. Goedert JJ. Reconstruction of the hepatitis C virus epidemic in the USA. *Lancet Infect Dis*. 2016 Sep;16(9):1007. PMID: 27684343
<https://reader.elsevier.com/reader/sd/pii/S1473309916301967?token=34149BFFC2C6809D5CCE8B6882833E427C7BDD51BBB8F5D53A538E108D9038C86A4CC172241DE9921360E9A2204039F6>
15. Kim, A. Hepatitis C Virus. *Ann Intern Med*. 2016 Sep 6;165(5):ITC33-ITC48. PMID: 27595226
<https://annals.org/aim/fullarticle/2547675/hepatitis-c-virus>
16. Eliminating the public health problem of hepatitis B and C in the United States: Phase One Report. National Academies of Sciences, Engineering, and Medicine. Washington (DC); 2016 Jun. PMID: 27336113
https://www.ncbi.nlm.nih.gov/books/NBK368070/pdf/Bookshelf_NBK368070.pdf
17. Joy JB, McCloskey RM, Nguyen T, et al. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. *Lancet Infect Dis*. 2016 June;16(6):698-702. PMID: 27039040
<https://reader.elsevier.com/reader/sd/pii/S1473309916001249?token=65B9C40910DE9DED0F5403B649E7CBBFB1CA4E61791C1905F6C865327272533218F6EF9C2CCD102E3321D1E1A9660C54>
18. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. *Clin Infect Dis*. 2016 May 15;62(10):1287-1288 PMID: 26936668
<https://academic.oup.com/cid/article/62/10/1287/2462772?searchresult=1>
19. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. *Gastroenterology*. 2010 Feb;138(2):513-521. PMID: 19861128
<https://reader.elsevier.com/reader/sd/pii/S001650850901885X?token=FD139D63CBB79E130337C52F8437ED38ADE9E5C54CBAED93559CE6AD32EEE711C939405380605AD0913A4A4D2D40EF01>

HCV in Rhode Island

1. Soipe AI, Taylor LE, Abioye AI, Green TC, Hadland SE, Marshall BDL. Prevalence of hepatitis C screening, testing, and care experience among young adults who use prescription opioids nonmedically. *J Adolesc Health*. 2018 Jan;62(1):114-117. PMID: 29102250
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742053/pdf/nihms905723.pdf>
2. Soipe AI, Razavi H, Razavi-Shearer D, Galárraga O, Taylor LE, Marshall BD. Chronic hepatitis C virus (HCV) burden in Rhode Island: modeling treatment scale-up and elimination. *Epidemiol Infect*. 2016 Aug 5:1-11. PMID:27492142.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562531/pdf/nihms883107.pdf>

3. Special Edition on Hepatitis C. *R I Med J*. 2014; 97(7). ISSN 2327 – 2228.

Alexander-Scott NE, Lemire A, Larson HE, Bandy U. Prevention and control of hepatitis C in Rhode Island. *R I Med J* (2013). 2014 Jul 1;97(7):25-28. PMID: 24983017

<http://rimed.org/rimedicaljournal/2014/07/2014-07-25-hepc-alexander-scott.pdf>

Joseph R, Kofman A, Larney S, Fitzgerald P. Hepatitis C Prevention and Needle Exchange Program in Rhode Island: ENCORE. *R I Med J* (2013). 2014 Jul 1;97(7):31-34. PMID: 24983019

<https://pdfs.semanticscholar.org/f50b/4b9d3c7ed51b97eacee8e6c5ee7da8d4c3f0.pdf>

Kinnard EN, Taylor LE, Galárraga O, Marshall BD. Estimating the true prevalence of hepatitis C in Rhode Island. *R I Med J* (2013). 2014 Jul 1;97(7):19-24. PMID: 24983016

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349508/pdf/nihms-666102.pdf>

Taylor LE. Hepatitis C virus infection: From Margin to Center in Rhode Island and Beyond. *R I Med J* (2013). 2014 Jul 1;97(7):15-6. PMID: 24983015

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374804/pdf/nihms671209.pdf>

Taylor LE. What price for a cure? *R I Med J* (2013). 2014 Jul 1;97(7):16-7. PMID: 25184174

HCV Policy

1. Cooper CL. Now Is the Time to Quickly Eliminate Barriers Along the Hepatitis C Cascade of Care. *J Infect Dis*. 2018 May 25;217(12):1858-1860. PMID: 29534217

<https://academic.oup.com/jid/article/217/12/1858/4925219>

2. Sood N, Ung D, Shankar A, Strom BL. A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries. *Ann Intern Med*. 2018 May 15.
3. Olafsson S, Tyrfinngsson T, Runarsdottir V, et al. Treatment as prevention for hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct-acting antiviral agents. *J Int Med*. 2018 May;283(5):500-507. PMID: 29512219

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.12740>

4. Pinsky B, Mitchell D, Gonzalez YS, Johnson S, Saab S. Early versus Delayed Hepatitis C Treatment Provides Increased Health Benefits at Lower Costs: A Pan-Genotypic Cost-Effectiveness Analysis Set in Scotland. Conference report at: European Association for the Study of the Liver. April 11-15, 2018.

<https://www.sciencedirect.com.uri.idm.oclc.org/science/article/pii/S0168827818302836>

5. Mahale P, Engels EA, Li R, et al. The effects of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. *Gut*. 2018 Mar;67(3):553-561. PMID: 28634198

https://gut.bmj.com/content/gutjnl/67/3/553.full.pdf?casa_token=uLV-hYWyjJ8AAAAA:XPewZT16rzsm94He-1HPSnmic1rO31w1g-57Tob0nC1XicLAOQfyvvi0hRO0FcgWLRb1er6H8TLBhA

6. Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination – A path to global elimination of hepatitis C. *J Hepatol*. 2017 Oct;67(4):665-666. PMID: 28760329

- <https://reader.elsevier.com/reader/sd/pii/S0168827817321414?token=852F435BFBE594938B9AB523E091D3162456028CA4FE3E39B463DF92DBF29BF77330E660E1D9C26229B3E4D055A1FC69>
7. Kim AY. The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective. *Clin Infect Dis*. 2017 Sep 1;65(5):709-711. PMID: 28575213
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850541/pdf/cix501.pdf>
 8. Cepeda JA, Thomas DL, Astemborski J, et al. Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study. *Clin Infect Dis*. 2017 Jul 15;65(2):235-243. PMID: 28329108
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850450/>
 9. Lasser KE, Heinz A, Battisti L, Akoumianakis A, Truong V, Tsui J, Ruiz G, Samet JH. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home. *Ann Fam Med* 2017 May;15(3):258-261. PMID: 28483892
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422088/pdf/0150258.pdf>
 10. Levin J, Gonzalez YS, Ingram A, et al. Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients. Conference report at: European Association for the Study of the Liver. April 19-23, 2017
<https://www.sciencedirect-com.uri.idm.oclc.org/science/article/pii/S0168827817319888>
 11. Grebely J, Litwin A, Dore GJ. Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. *J Viral Hepat*. 2016 Sep;23(9):664-666. PMID: 27272285
<https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12550>
 12. Edlin B. Access to treatment for hepatitis C virus infection: time to put patients first. *Lancet Infect Dis*. 2016 Sep;16(9):e196-e201. PMID: 27421993
<https://reader.elsevier.com/reader/sd/pii/S1473309916300056?token=BB3FC2D281A19D8DFE13D9B1B21729207F88A4149CEE544B1A37B08A009843356A1F9B473262F2817564C7393E6730D1>
 13. Ryerson AB, Ehemann CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. *Cancer*. 2016 May 1;122(9): 1312-1337. PMID: 26959385
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840031/pdf/nihms773185.pdf>
 14. Edlin B, Eckhardt B, Shu M, Holmberg S, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. *Hepatology*. 2015 Nov;62(5):1353-1363. PMID: 2729352
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751870/pdf/nihms-756518.pdf>
 15. Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. *Hepatology*. 2015 Nov;62(5): 1396-1404. PMID: 26126725
<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.27966>
 16. Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. *Clin*

- Gastroenterol Hepatol.* 2015 Oct;13(10):1711-1713. PMID: 26091736
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575858/pdf/nihms704977.pdf>
17. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med.* 2015 Aug 4;163(3):215-23. PMID: 26120969.
<https://annals.org/aim/article-abstract/2362306>
 18. Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. *Clin Infect Dis.* 2015 Jul 15;61(2):169-170. PMID: 25778748.
<https://academic.oup.com/cid/article/61/2/169/328648>
 19. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. *Ann Intern Med.* 2015 Mar 17;162(6):407-419. PMID: 25775313
https://scholar.harvard.edu/files/alexiskrumme/files/2015_cost_effectiveness_novel_regimens_hcv.pdf
 20. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med.* 2015 Mar 17;162(6):397-406. PMID: 25775312
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435698/pdf/nihms682787.pdf>
 21. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. *Clin Infect Dis.* 2015;61(2):157-168. PMID: 25778747
<https://academic.oup.com/cid/article/61/2/157/328531>
 22. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. *Clin Infect Dis.* 2015 Jun 15;60(12): 1743-1751. PMID: 25733369
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834854/pdf/civ170.pdf>
 23. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. *Hepatology.* 2015 Jun;61(6):1860-1869. PMID: 25677072
<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.27736>
 24. Kofman A, Litwin AH, Swan T, Pinkston M, Rizzo B, Bryant V, Taylor LE. Short Communication: Heterogeneity in Drug and Alcohol Use-Related Exclusion Criteria in Direct Acting Antiviral Agent Hepatitis C Treatment Trials for Individuals Coinfected with Hepatitis C Virus and HIV. *Clin Res HIV/AIDS.* 2015;2(2):1019.
 25. Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology.* 2014 Sep;60(3):832-843. PMID: 25043847
<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.27296>
 26. Kottlil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection: is it time for the internist to take the reins? *Ann Intern Med.* 2014 Sep 16;161(6):443-444. PMID: 25222390
<http://www.natap.org/2014/HCV/0000605-201409160-00012.pdf>

27. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? *Hepatology*. 2014 Apr;59(4):1246-1249. PMID: 24493069
<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.27039>
28. Kanwal F, El-Serag HB. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. *Clin Gastroenterol Hepatol*. 2014;12(8):1381-1383. PMID: 24607698
[https://www.cghjournal.org/article/S1542-3565\(14\)00349-8/pdf](https://www.cghjournal.org/article/S1542-3565(14)00349-8/pdf)
29. Casalino LP. Professionalism and Caring for Medicaid Patients-- The 5% Commitment? *N Eng J Med*. 2013 Nov 7;369(19):1775-1777. PMID: 24106910
<https://www.nejm.org/doi/pdf/10.1056/NEJMp1310974?articleTools=true>
30. Ellwood M, Greenwald R, Blankstein SF, et al. Improving the Response to Hepatitis C Virus (HCV) in Massachusetts: Executive Summary. *SHARP: State Healthcare Access Research Project*. Apr 2013.
31. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW, Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *Morbidity and Mortality Weekly Report*. 2012 Aug 17;61(RR-4):1-32. PMID: 22895429
<https://www.cdc.gov/mmwr/pdf/rr/rr6104.pdf>
32. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med*. 2012 Feb 21;156(4):271-278. PMID: 22351712
<https://annals.org/aim/fullarticle/1169805/increasing-burden-mortality-from-viral-hepatitis-united-states-between-1999>
33. Grebely J, Dore GJ. What Is killing people with hepatitis C virus infection? *Semin Liver Dis*. 2011 Nov;31(4):331-339. PMID: 22189973
https://www.researchgate.net/profile/Jason_Grebely/publication/51905903_What_Is_Killing_People_with_Hepatitis_C_Virus_Infection/links/00b49530bb8650f065000000.pdf
34. Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: who should be first in line? *Hepatology*. 2011 Jun;53(6):1789-1791. PMID: 21520197
<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.24374>
35. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. *N Engl J Med*. 2011 Jun 9;364(23):2199-2207. PMID: 21631316
<https://www.nejm.org/doi/pdf/10.1056/NEJMoa1009370?articleTools=true>
36. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. *Hepatology*. 2010 Sep;52(3):1124-1133. PMID: 20607688
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795614/pdf/nihms-461624.pdf>

HCV Screening

1. Jonas MC, Rodriguez CV, Redd J, et al. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. *Clin Infect Dis*. 2016 May 15;62(10):1290-1296. PMID: 26908812
<https://academic.oup.com/cid/article/62/10/1290/2462676>
2. Durham DP, Skrip LA, Bruce RD, et al. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. *Clin Infect Dis*. 2016 Feb 1;62(3):298-304. PMID: 26628566
<https://academic.oup.com/cid/article/62/3/298/2462968>
3. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? *BMJ*. 2015 Jan 13;350:g7809-g7809. PMID: 25587052
<https://www.jstor.org/stable/pdf/26517873.pdf>
4. Smith BD, Yartel AK, Krauskopf K, et al. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. *Clin Infect Dis*. 2015 Apr;60(8):1145-1152. PMID: 25595745
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796763/pdf/nihms937203.pdf>
5. Boschert S. Best HCV value? Screen All Baby Boomers, Treat All. *Internal Medicine News*. 2014 Dec:19-21.
<https://www.mdedge.com/clinicianreviews/article/88872/gastroenterology/best-hcv-value-screen-all-baby-boomers-treat-all>
6. Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH. The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. *AIDS Patient Care STDS*. 2014 Jan;28(1):4-9. PMID: 24428794
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894677/pdf/apc.2013.0130.pdf>

HCV and People Who Inject Drugs (PWID)

1. Artenie AA, Minoyan N, Jacka B, et al. Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. *CMAJ*. 2019 Apr 29;191(17):E462-E468. PMID: 31036608
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488472/pdf/191e462.pdf>
2. Heimer R, Hawk K, Vermund SH. Prevalent misconceptions about opioid use disorders in the United States produce failed policy and public health responses. *Clin Infect Dis*. 2018 Nov 17;. doi: 10.1093/cid/ciy977. PMID: 30452633
<https://academic.oup.com/cid/article/69/3/546/5188003>
3. Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. *Infect Dis Clin North Am*. 2018 Jun;32(2):347-370. PMID: 29778260
<https://www.ncbi.nlm.nih.gov/pubmed/29778260/>
4. Jones CM, Einstein EB, Compton WM. Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016. *JAMA*. 2018 May 1;319(17):1819-1821. PMID: 29715347
<https://jamanetwork.com/journals/jama/fullarticle/2679931>

5. Martin SA, Bosse J, Wilson A, Losikoff P, Chiodo L. Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care. *Addict Sci & Clin Pract.* 2018 Apr 25; 13(1):10. PMID: 29690936
<https://ascjournal.biomedcentral.com/track/pdf/10.1186/s13722-018-0111-7>
6. Liang JT, Ward JW. Hepatitis C in Injection-Drug Users – A Hidden Danger of the Opioid Epidemic. *N Eng J Med.* 2018 Mar 29;378(13):1169-1171. PMID: 29601263
<https://www.nejm.org/doi/pdf/10.1056/NEJMp1716871?articleTools=true>
7. Innes H, McAuley A, Alavi M, et al. The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort-study. *Hepatology.* 2018 Jan;67(1):97-107. PMID: 28777874
<https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29419>
8. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 19-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.
https://www.ncbi.nlm.nih.gov/books/NBK535268/pdf/Bookshelf_NBK535268.pdf
9. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 19-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.
https://store.samhsa.gov/system/files/tip63_fulldoc_052919_508.pdf
10. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health.* 2017 Dec;5(12):e1192-e1207. PMID: 29074409
<https://www.thelancet.com/action/showPdf?pii=S2214-109X%2817%2930375-3>
11. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. *Clin Infect Dis.* 2016 Dec 1;63(11):1479-1481. PMID: 27553377
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106608/pdf/ciw579.pdf>
12. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. *Ann Intern Med.* 2016 Nov 1;165(9):625-634. PMID: 27537841
http://1yh21u3cjptv3xjder1dco9mx5s.wpengine.netdna-cdn.com/wp-content/uploads/2016/08/Dore_HCV-in-OAT-Patients_Ann-Int-Med_2016.pdf
13. Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? *J Hepatol.* 2015 Oct;63(4):779-82. PMID: 26254264
[https://www.journal-of-hepatology.eu/article/S0168-8278\(15\)00406-7/pdf](https://www.journal-of-hepatology.eu/article/S0168-8278(15)00406-7/pdf)

14. Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Llyod AR, Mauss S, Prins M, Swan T, Schaefer M, Tatlor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy*. 2015 Oct;26(10):1028-1038. PMID: 26282715

<https://reader.elsevier.com/reader/sd/pii/S0955395915002066?token=2F32361BD4A77575F78C21BD8BA6932B4E9C3E6D2AAE441AB5D074C3191CFFC48AC5354B6677C83600ADEE67D020D70F>
15. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who injected drugs (PWID): A systematic review and meta-analysis. *Int J Drug Pol*. 2015 Oct;26:911-921. PMID: 26298331

<https://reader.elsevier.com/reader/sd/pii/S0955395915002054?token=E9B157AD7C274D069385CE8DA435380862DA9A44FAF52ED6B3440C59DBAC7F340D3AA5E681EC6D01C9471F2EF36BC84E>
16. Batchelder AW, Peyser D, Nahvi S, Amsten JH, Litwin AH. "Hepatitis C treatment turned me around." Psychological and behavioral transformation related to hepatitis C treatment. *Drug Alcohol Depend*. 2015 Aug 1;153:66-71. PMID: 26096534

<https://reader.elsevier.com/reader/sd/pii/S0376871615003038?token=7A76F4C2186C86262D910EED7804E39364B00C5EF31D4A3CA9413F82D9852E184A956CC8A12822635167B514C8A4CF8E>
17. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? *Antiviral Res*. 2014 Oct;110:79-93. PMID: 25110202

<https://reader.elsevier.com/reader/sd/pii/S0166354214002149?token=504347B640D99F00F0A60FB49C93B02A2CFDE1DA4CCB85921F9FE8C2DCD653DA41087926183CBD5EF85B7C36B56D51FB>
18. Arain A, Robaey G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. *World J Gastroenterol*. 2014 Sep 28;20(36):12722-12733. PMID: 25278674

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177459/pdf/WJG-20-12722.pdf>
19. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? *Antiviral Res*. 2014 Apr;104:62-72. PMID: 24468275

<https://reader.elsevier.com/reader/sd/pii/S016635421400014X?token=1548B5A2C3C7E84A6484A3C839D0727439962D9FC76B50B533498078A3A6137CAE59DF75D6B54F2AB98F29C61E67852A>
20. Treloar C, Rance J, Dore GJ, Grebely J; ETHOS Study Group. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. *J Viral Hepat*. 2013 Aug;21(8):560-567. PMID: 24299222

<https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12183>
21. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster Gr, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology*. 2013;58(5):1598-1609. PMID: 23553643

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26431>

22. Robaey G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor LE, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis*. 2013 Aug;57(suppl 2):S129-S137. PMID: 23884061

<https://reader.elsevier.com/reader/sd/pii/S0955395915002066?token=CCA2EC1D0CDE5AB8C387BEB1137E4A5AEB49CD8DC2F38505C7372020E9AB060817A813EF475D4DF505BF672068E5918C>
23. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis*. 2013 Aug;57 Suppl 2:S118-24. PMID: 23884059

https://academic.oup.com/cid/article/57/suppl_2/S118/399169
24. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. *J Infect Dis*. 2013 Mar;207 Suppl 1:S19–25. PMID: 23390301

https://academic.oup.com/jid/article/207/suppl_1/S19/853931
25. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology*. 2012 Jan;55(1):49-57. PMID: 21898506

<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.24656>
26. Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe P, Maynard M, McGovern BH. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. *Drug Alcohol Depend*. 2011 Jul 1;116(1-3):233-237. PMID: 21177046

<https://reader.elsevier.com/reader/sd/pii/S0376871610004126?token=3C936484E70D02F8583D100BFA121C14E7D4E76C5462B22EFF337E6814A907B042745B111360F3314416723F8FBFCF31>
27. Jürgens R, Csete J, Amon JJ, et al. People who use drugs, HIV, and human rights *Lancet*. 2010 Aug 7;376(9739):475-485. PMID: 20650514

<https://reader.elsevier.com/reader/sd/pii/S0140673610608306?token=ED9A3EF8F735617C9F6CD8D639A1773CA6A2840B81421209EBF72DEAD2C207211BAA261D39C94C86D94D36A1442F88B9>
28. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. *Addiction*. 2004 Sep;99(9):1167-1175. PMID: 15317637

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1360-0443.2004.00821.x>
29. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? *N Engl J Med*. 2001 Jul 19;345(3):211-215. PMID: 11463019

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510901/pdf/nihms-7161.pdf>

Patient-reported outcomes with DAAs

1. Stepanova M, Thompson A, Doyle J, et al. Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens. *J Infect Dis.* 2018 Mar 13;217(7):1033-1043. PMID: 29293991
<https://academic-oup-com.uri.idm.oclc.org/jid/article/217/7/1033/4774699>
2. Perumalswami PV, Talal AH. Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders. *J Infect Dis.* 2018 Mar 13;217(7):1020-1023. PMID: 29294033
<https://academic.oup.com/jid/article/217/7/1020/4774700>

HCV and Alcohol Use

1. Kelly EM, Dodge JL, Bacchetti P, et al. Moderate alcohol use is not associated with fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected women: A prospective cohort study. *Clin Infect Dis.* 2017 Nov 29;65(12): 2050-2056. PMID: 29020382
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850438/pdf/cix716.pdf>
2. Le Lan C, Guillygomarc'h A, Danielou H, et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. *J Hepatol.* 2012 Feb;56(2):334-340. PMID: 21756854.
<https://reader.elsevier.com/reader/sd/pii/S0168827811005253?token=C7722D75EC09EEF12E351858FCCB419E2D044876AE7C4EEC7E0EFDDC523A84EC2C88CC8EE08C76789C5B8D986C0260FD>
3. Bruggmann P, Dampz M, Gerlach T, et al. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study. *Drug Alcohol Depend.* 2010 Jul 1;110(1-2):167-171. PMID: 20334985.
<https://reader.elsevier.com/reader/sd/pii/S0376871610000931?token=C0A9ADAF09C081E83BA68DDD06C3B3CF15895BC0E821EAE1DC3635C4F1690C1740391189828D2F76801F8DB8E538051C>
4. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. *J Clin Gastroenterol.* 2007 Sep;41(8):761-772. PMID: 17700425
<https://insights.ovid.com/pubmed?pmid=17700425>
5. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, Wright T, VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. *Gastroenterology.* 2006 May;130(6):1607-1616. PMID: 16697724
[https://www.gastrojournal.org/article/S0016-5085\(06\)00334-9/pdf](https://www.gastrojournal.org/article/S0016-5085(06)00334-9/pdf)
6. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. *Clin Gastroenterol and Hepatol.* 2005 Nov;3(11):1150-1159. PMID: 16271348
<https://www.sciencedirect.com/science/article/abs/pii/S1542356505004076?via%3Dihub>
7. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology.* 1998 Apr;27(4):914-919. PMID: 9537428

<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.510270404>

8. Rosman AS, Waraich A, Galvin K, et al. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. *Am J Gastroenterol*. 1996 Mar;91(3):498-505. PMID: 8633498

HCV/HIV Coinfection

1. Moore DJ, Jain S, Dube MP, et al. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. *Clin Infect Dis*. 2018 May 2;66(10): 1566-1572. PMID: 29228144
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248545/pdf/cix1055.pdf>
2. Mogalian E, Stamm LM, Osinusi A, et al. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. *Clin Infect Dis*. 2018 Mar 7. PMID: 29522076
<https://academic.oup.com/cid/article/67/6/934/4924529>
3. Graham CS. Hepatitis C and HIV co-infection: closing the gaps. *JAMA*. 2015 Mar 24-31;313(12):1217-1218. PMID: 25705993
<https://jamanetwork.com/journals/jama/fullarticle/2173264>
4. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents- A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: considerations for antiretroviral use in patients with coinfections. 2014 Nov.
<https://aidsinfo.nih.gov/contentfiles/adultandadolescentgl003093.pdf>
5. U.S. Department of Health and Human Services Health Resources and Services Administration HIV/AIDS Bureau, Special Projects of National Significance Program. Training and Implementing Guide: Delivering Hepatitis C Treatment in an HIV Care Setting. 2014 Sep.
<https://targethiv.org/ihip/delivering-hepatitis-c-treatment-hiv-care-setting>
6. Freiman JM, Huang W, White LF, Geng EH, Hurt CB, Taylor LE, Overton ET, Cachay ER, Kitahata MM, Moore RD, Rodriguez B, Mayer KH, Linas BP. Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. *Clin Infect Dis*. 2014 Dec 15;59(12):1686-1693. PMID: 25186591
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311177/pdf/ciu698.pdf>
7. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis*. 2013 Aug;57 Suppl 2:S118-24. PMID: 23884059
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722078/pdf/cit326.pdf>
8. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis*. 2013 May;56(10):1480-7. PMID: 23386630
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634307/pdf/cit054.pdf>
9. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. *Clin Infect Dis*. 2012 Jul;55 Suppl 1:S33-42. PMID: 22715212

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491862/pdf/cis367.pdf>

10. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. *Clin Infect Dis*. 2011 Mar 15;52(6):812-8. PMID: 21282184

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106260/pdf/ciq201.pdf>

11. Taylor LE. HIV/viral hepatitis coinfection: the Immunology Center experience. *Med Health R.I.* 2009 Jul;92(7):234-6. PMID: 19685638

<https://pdfs.semanticscholar.org/55fb/8caff82f351998a86eb73f8eae3966647e93.pdf>

Evaluating Fibrosis

1. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. *Int J Drug Policy*. 2015 Oct;26(10):911-921. PMID: 26298331

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577462/pdf/nihms717449.pdf>

2. Berenguer J, Zamora FX, Aldámiz-Echevarría T, et al; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfecting with HIV and hepatitis C virus. *Clin Infect Dis*. 2015 Mar 15;60(6):950-958. PMID: 25422386

<https://academic.oup.com/cid/article/60/6/950/497205>

3. Holmberg SD, Lu M, Rupp LB, et al; Chronic Hepatitis Cohort Study (CHcCs) Investigators. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. *Clin Infect Dis*. 2013 Jul;57(2):240-246. PMID: 23592832

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672918/pdf/nihms916714.pdf>

HCV and Cirrhosis

1. Yadav A, Vargas HE. Care of the patient with cirrhosis. *Clin Liver Dis*. 2015 May 7;5(4):100-104.

<https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/cld.462>

2. Ge PS, Runyon BA. Serum ammonia level for the evaluation of hepatic encephalopathy. *JAMA*. 2014 Aug 13;312(6):643-644. PMID: 25117134

<https://jamanetwork.com/journals/jama/fullarticle/1895229>

3. Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, Schulzer M, Mak E, Yoshida EM. Does This Patient With Liver Disease Have Cirrhosis? *JAMA*. 2012 Feb;307(8):832-842

<https://jamanetwork.com/journals/jama/fullarticle/1355997>

Vetted Websites

* <http://hcvguidelines.org> The American Association for the Study of Liver Diseases (AASLD) and Infectious Disease Society of America (IDSA) develops evidence-based practice guidelines for testing, managing, and treating hepatitis C.

* <http://ridefeatshepc.com/>

* <https://www.hepatitisc.uw.edu/> University of Washington: Hepatitis C Online curriculum with

free continuing education credits

- <http://www.cdc.gov/hepatitis/hcv/>
- <http://www.who.int/hepatitis/en/>
- <http://www.treatmentactiongroup.org/hcv>
- <http://www.natap.org/>
- <http://hcvadvocate.org/>
- <http://www.oasiscliniconline.org/>
- <http://nvhr.org/>
- <http://www.hepeducation.org/>
- <http://hcvtreatmentaccess.org/>